Lymphoma

From Blink-182 bandmember Mark Hoppus’s cancer update to Olympian Elizabeth Beisel’s swim for cancer, here’s what’s happening in the cancer landscape this week.

While the recent FDA approval of Jakafi offers another effective option for patients with chronic GVHD, one expert urges that more work needs to be done to prevent and/or reverse the condition.

Certain races/ethnicities and ages may have worse outcomes in Hodgkin lymphoma regardless of variation in upfront chemotherapy.

The tome also reflects on his own diagnosis of cancer and how it influenced his practice.

The FDA has granted approval to Jakafi (ruxolitinib) for the treatment of chronic graft-versus-host disease (GVHD).

Patients with blood cancer who underwent stem cell transplant and developed chronic graft-versus-host disease have more treatment options than ever before. But the formula for planning older and newer therapies has not yet been established.

From Jeff Bridges achieving remission from cancer to a cancer survivor who became a runway model, here’s what’s happening in the cancer landscape this week.

Patients with relapsed/refractory, pretreated marginal zone lymphoma are now eligible for treatment with Brukinsa.

Circulating tumor DNA found in blood plasma may help predict if the likelihood of relapse for patients with large B-cell lymphoma, according to recent research.

The use of convalescent plasma therapy in patients with blood cancers and COVID-19 was associated with an improvement in survival from the infection.

The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.

A recent webinar from the Lymphoma Research Foundation gave important advice for caregivers, including the importance of taking care of oneself.

Patients with blood cancers may be less likely to derive immunity from the COVID-19 vaccine, though antibody tests should not be the end-all-be-all in guiding their behavior.

Researchers are evaluating the safety and efficacy of zandelisib, an investigational cancer therapy, for the treatment of patients with marginal zone lymphoma and follicular lymphoma who have received at least two prior therapies.

Combining PI3 kinase inhibitors with BTK inhibitors can mitigate side effects traditionally seen with PI3 kinase inhibitors, according to recent research.

In this episode of the “CURE® Talks Cancer” podcast, Olympic triathlete Kevin McDowell discusses his cancer journey and shares some insight on his experiences at the Tokyo 2020 Olympics.

Adolescent and young adult patients are more represented than previously expected in clinical trials. However, their outcomes still lag behind the younger and older populations.

Blood cancer survivors are living longer than ever, making safe pain management an important concern.

In his new memoir, a patient with central nervous system lymphoma emphasizes the importance of a positive mindset and a strong support system.

Nina Luker, a healthy 25 year old, felt invincible. But she says that "naïve perspective was disrupted in a matter of hours."

Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

From a 90-year-old man’s 3,600-mile walk to raise money for children with cancer to the death of KISS and Cinderella keyboardist Gary Corbett, here’s what’s happening in the cancer landscape this week.

The FDA approval of Rylaze provides certain patients with leukemia and lymphoma with an on-demand treatment option since the only other approved therapy is currently undergoing a shortage.

Monjuvi and Revlimid attained extended remission and improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma.